Search Results - "Lategahn, Jonas"

Organocatalytic, Oxidative, Intramolecular CH Bond Amination and Metal-free Cross-Amination of Unactivated Arenes at Ambient Temperature by Antonchick, Andrey P., Samanta, Rajarshi, Kulikov, Katharina, Lategahn, Jonas

“…The twinkling of an I: In a new atom‐economical and environmentally friendly organocatalytic method for intramolecular CH amination, the CN bond forms at…”
Get full text

Metal-free direct oxidative intermolecular diarylation of anilides at ambient temperature assisted by cascade selective formation of C-C and C-N bonds by Samanta, Rajarshi, Lategahn, Jonas, Antonchick, Andrey P

“…A new atom-economical process of direct oxidative intermolecular functionalization of aniline derivatives by simple arenes was developed. The products were…”
Get more information

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site by Günther, Marcel, Lategahn, Jonas, Juchum, Michael, Döring, Eva, Keul, Marina, Engel, Julian, Tumbrink, Hannah L, Rauh, Daniel, Laufer, Stefan

“…Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance…”
Get full text

Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain by Grunewald, Susanne, Klug, Lillian R, Mühlenberg, Thomas, Lategahn, Jonas, Falkenhorst, Johanna, Town, Ajia, Ehrt, Christiane, Wardelmann, Eva, Hartmann, Wolfgang, Schildhaus, Hans-Ulrich, Treckmann, Juergen, Fletcher, Jonathan A, Jung, Sascha, Czodrowski, Paul, Miller, Stephen, Schmidt-Kittler, Oleg, Rauh, Daniel, Heinrich, Michael C, Bauer, Sebastian

“…Gastrointestinal stromal tumors (GIST) harboring activating mutations of respond to imatinib, with the notable exception of the most common mutation, D842V…”
Get more information

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor by Tomassi, Stefano, Lategahn, Jonas, Engel, Julian, Keul, Marina, Tumbrink, Hannah L, Ketzer, Julia, Mühlenberg, Thomas, Baumann, Matthias, Schultz-Fademrecht, Carsten, Bauer, Sebastian, Rauh, Daniel

“…The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in…”
Get full text

A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives by do Amaral, Daniel Nascimento, Lategahn, Jonas, Fokoue, Harold Hilarion, da Silva, Eduardo Miguez Bastos, Sant’Anna, Carlos Mauricio R., Rauh, Daniel, Barreiro, Eliezer J., Laufer, Stefan, Lima, Lidia Moreira

“…Clinical data acquired over the last decade on non-small cell lung cancer (NSCLC) treatment with small molecular weight Epidermal Growth Factor Receptor (EGFR)…”
Get full text

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors by Fassunke, Jana, Müller, Fabienne, Keul, Marina, Michels, Sebastian, Dammert, Marcel A., Schmitt, Anna, Plenker, Dennis, Lategahn, Jonas, Heydt, Carina, Brägelmann, Johannes, Tumbrink, Hannah L., Alber, Yannic, Klein, Sebastian, Heimsoeth, Alena, Dahmen, Ilona, Fischer, Rieke N., Scheffler, Matthias, Ihle, Michaela A., Priesner, Vanessa, Scheel, Andreas H., Wagener, Svenja, Kron, Anna, Frank, Konrad, Garbert, Katia, Persigehl, Thorsten, Püsken, Michael, Haneder, Stefan, Schaaf, Bernhard, Rodermann, Ernst, Engel-Riedel, Walburga, Felip, Enriqueta, Smit, Egbert F., Merkelbach-Bruse, Sabine, Reinhardt, H. Christian, Kast, Stefan M., Wolf, Jürgen, Rauh, Daniel, Büttner, Reinhard, Sos, Martin L.

“…The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients…”
Get full text

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors by Fassunke, Jana, Müller, Fabienne, Keul, Marina, Michels, Sebastian, Dammert, Marcel A, Schmitt, Anna, Plenker, Dennis, Lategahn, Jonas, Heydt, Carina, Brägelmann, Johannes, Tumbrink, Hannah L, Alber, Yannic, Klein, Sebastian, Heimsoeth, Alena, Dahmen, Ilona, Fischer, Rieke N, Scheffler, Matthias, Ihle, Michaela A, Priesner, Vanessa, Scheel, Andreas H, Wagener, Svenja, Kron, Anna, Konrad, Frank, Garbert, Katia, Persigehl, Thorsten, Püsken, Michael, Haneder, Stefan, Schaaf, Bernhard, Rodermann, Ernst, Engel-Riedel, Walburga, Felip, Enriqueta, Smit, Egbert F, Merkelbach-Bruse, Sabine, Reinhardt, H Christian, Kast, Stefan M, Wolf, Jürgen, Rauh, Daniel, Büttner, Reinhard, Sos, Martin L

“…The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients…”
Get full text

Lessons To Be Learned: The Molecular Basis of Kinase‐Targeted Therapies and Drug Resistance in Non‐Small Cell Lung Cancer by Lategahn, Jonas, Keul, Marina, Rauh, Daniel

“…The treatment of non‐small cell lung cancer (NSCLC) is currently experiencing a revolution. Over the last decade, the knowledge gained about the biochemical…”
Get full text

C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer? by Grabe, Tobias, Lategahn, Jonas, Rauh, Daniel

“…The first evidence of osimertinib resistance mediated by the epidermal growth factor receptor (EGFR) mutation C797S was reported three years ago. Since then,…”
Get full text

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer by Engel, Julian, Lategahn, Jonas, Rauh, Daniel

“…In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the…”
Get full text

Organokatalytische, oxidative, intramolekulare C‐H‐Bindungsaminierung und metallfreie Kreuzaminierung nichtaktivierter Arene bei Raumtemperatur by Antonchick, Andrey P., Samanta, Rajarshi, Kulikov, Katharina, Lategahn, Jonas

“…Metallfrei: Eine atomökonomische, umweltverträgliche und organokatalytische Methode zur intramolekularen C‐H‐Aminierung wurde entwickelt. Die Bildung der…”
Get full text

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases by Niggenaber, Janina, Hardick, Julia, Lategahn, Jonas, Rauh, Daniel

“…The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of…”
Get full text

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases: Miniperspective by Niggenaber, Janina, Hardick, Julia, Lategahn, Jonas, Rauh, Daniel

“…The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of…”
Get full text

Characterization of Covalent Pyrazolopyrimidine–MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7) by Wolle, Patrik, Engel, Julian, Smith, Steven, Goebel, Lisa, Hennes, Elisabeth, Lategahn, Jonas, Rauh, Daniel

“…Pyrazolopyrimidines are well-established as covalent inhibitors of protein kinases such as the epidermal growth factor receptor or Bruton’s tyrosine kinase,…”
Get full text

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR by Engel, Julian, Becker, Christian, Lategahn, Jonas, Keul, Marina, Ketzer, Julia, Mühlenberg, Thomas, Kollipara, Laxmikanth, Schultz-Fademrecht, Carsten, Zahedi, René P., Bauer, Sebastian, Rauh, Daniel

“…Targeting acquired drug resistance represents the major challenge in the treatment of EGFR‐driven non‐small‐cell lung cancer (NSCLC). Herein, we describe the…”
Get full text

Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands by Niggenaber, Janina, Heyden, Leonie, Grabe, Tobias, Müller, Matthias P, Lategahn, Jonas, Rauh, Daniel

“…Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) and currently the gold-standard for the treatment of patients suffering from non-small cell…”
Get full text

Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c-Jun N‑Terminal Kinase) Pathway with Covalent Inhibitors by Wolle, Patrik, Hardick, Julia, Cronin, Shane J. F, Engel, Julian, Baumann, Matthias, Lategahn, Jonas, Penninger, Josef M, Rauh, Daniel

“…The protein kinase MKK7 is linked to neuronal development and the onset of cancer. The field, however, lacks high-quality functional probes that would allow…”
Get full text

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach by Engel, Julian, Richters, André, Getlik, Matthäus, Tomassi, Stefano, Keul, Marina, Termathe, Martin, Lategahn, Jonas, Becker, Christian, Mayer-Wrangowski, Svenja, Grütter, Christian, Uhlenbrock, Niklas, Krüll, Jasmin, Schaumann, Niklas, Eppmann, Simone, Kibies, Patrick, Hoffgaard, Franziska, Heil, Jochen, Menninger, Sascha, Ortiz-Cuaran, Sandra, Heuckmann, Johannes M., Tinnefeld, Verena, Zahedi, René P., Sos, Martin L., Schultz-Fademrecht, Carsten, Thomas, Roman K., Kast, Stefan M., Rauh, Daniel

“…Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals,…”
Get full text

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape by Mühlenberg, Thomas, Falkenhorst, Johanna, Schulz, Tom, Fletcher, Benjamin S, Teuber, Alina, Krzeciesa, Dawid, Klooster, Isabella, Lundberg, Meijun, Wilson, Lydia, Lategahn, Jonas, von Mehren, Margaret, Grunewald, Susanne, Tüns, Alicia Isabell, Wardelmann, Eva, Sicklick, Jason K, Brahmi, Mehdi, Serrano, César, Schildhaus, Hans-Ulrich, Sievers, Sonja, Treckmann, Jürgen, Heinrich, Michael C, Raut, Chandrajit P, Ou, Wen-Bin, Marino-Enriquez, Adrian, George, Suzanne, Rauh, Daniel, Fletcher, Jonathan A, Bauer, Sebastian

“…Imatinib resistance in GI stromal tumors (GISTs) is primarily caused by secondary mutations, and clonal heterogeneity of these secondary mutations represents a…”
Get full text